Evidence mapPaperPMID 41695696Full record

ReviewPeerJ2026

Mastering cardiomyocyte mitophagy: molecular governance, pathological derailment and therapeutics.

Pan Liu, Haosheng Wu, Huanhuan Ren, Jing Wang, Fan Yang

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pan LiuZhongyi School, Anhui University of Chinese Medicine, Hefei, China.ORCID 0000-0001-9222-0323
Haosheng WuZhongyi School, Anhui University of Chinese Medicine, Hefei, China.
Huanhuan RenZhongyi School, Anhui University of Chinese Medicine, Hefei, China.
Jing WangZhongyi School, Anhui University of Chinese Medicine, Hefei, China.
Fan YangDepartment of Cardiology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitophagy is a pivotal quality control pathway that maintains cardiac energy metabolism and structural stability by selectively removing damaged or senescent mitochondria, thereby keeping mitochondrial dynamics in balance. This process secures cardiomyocyte survival, calcium handling, and contractile function during both rest and stress. When mitophagic flux is inadequate, accumulation of reactive oxygen species, disruption of calcium homeostasis, and uncontrolled inflammation act together to drive pathological hypertrophy, heart failure, cardiac aging, and obesity-associated cardiomyopathy. Conversely, appropriate activation of mitophagy can lessen structural injury and restore pump performance during ischemia reperfusion, pressure overload, and metabolic stress. This review summarizes the central regulatory network of cardiac mitophagy and its pathological roles across cardiovascular disorders, emphasizing that careful modulation of flux is essential for preserving myocardial homeostasis. Recent experimental strategies that target mitophagy are also discussed, providing a theoretical foundation for the development of precise cardioprotective therapies.

Indexed as

Mitochondria, HeartMitophagyMyocytes, CardiacAnimalsEnergy MetabolismHumansReactive Oxygen SpeciesReactive Oxygen SpeciesCardiac agingCardiac hypertrophy and heart failureCardiomyocyteMitophagy

Identifiers

PMID41695696
PMCPMC12903907

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.